F 0757
Ensure each resident’s drug regimen must be free from unnecessary drugs.
Level of Harm - Immediate
jeopardy to resident health or
safety
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review, the facility failed to obtain physician ordered laboratory testing in 1 of 3
residents (R2), reviewed for medication monitoring in the sample of 9. This failure resulted in R2 being
admitted to the hospital on [DATE], where he remains. R2 was diagnosed in the hospital with
Supratherapeutic INR (Initial Normalized Ratio) with a level greater than 10 (target range is between 2-3)
and had to receive medication to reverse the effects from the anticoagulant, Warfarin, that R2 was receiving
in the facility for a diagnosis of Pulmonary Embolism. This failure resulted in an immediate jeopardy when
the facility failed to obtain laboratory testing to monitor R2's anticoagulant levels to ensure a therapeutic
level was obtained.
Residents Affected - Few
The Immediate Jeopardy began on 4/23/24, when the facility failed to obtain a PT(Prothromin Time)/INR to
ensure a therapeutic level was obtained due to the use of an anticoagulant. On 5/21/25 at 9:35 AM, V1,
Administrator, V7, Regional Director of Operations, and V8, Chief Operating Officer, were notified of the
Immediate Jeopardy. The surveyor confirmed by observation, interview and record review, the Immediate
Jeopardy was removed on 5/22/25, but remains at Level Two because additional time is needed to evaluate
the implementation and effectiveness of the in-service training.
Findings include:
On 5/20/25 at 10:30 AM, V5, R2's Sister, stated R2 is currently in the hospital preparing for surgery to
remove a large cancerous mass in his intestines. V5 stated she is concerned about R2's Coumadin not
being checked at the facility like it is supposed to be, it is to be checked weekly and hasn't been checked
since March 2025. V5 stated when R2 was in the ER (Emergency Room) his blood count was 3 and his
INR which is supposed to be between 1-2 was greater than 10. V5 stated this is not acceptable and
whoever is to be checking to make sure his INR is being checked failed, the bedside care and the nurses
are good at the facility and have saved R2's life a few times, but this is unacceptable.
R2's ER (Emergency Room) Notes, dated 5/8/25, document R2's INR was greater than 10, R2 was started
on Vitamin K and Kcentra (medication used to reverse the effects of Warfarin). Admit to ICU (Intensive Care
Unit) for multiple problems, critically ill patient. Impression: Sepsis, Leukocytosis, GI (Gastrointestinal)
Bleed, Elevated Lactic Acid Level, Elevated INR.
R2's History and Physical, dated 5/8/25, documents the following: Impression - Acute Blood Loss Anemia,
Probable GI Bleed, Supratherapeutic INR, Hx of PE. Reversal of Coumadin with Kcentra.
R2's Hospital Laboratory Results, dated 5/8/25, document R2's Hgb (Hemoglobin) level was 3.8 (normal
range is 14 - 18); PT (Prothrombin Time) level of greater than 80 seconds (normal range is
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 4
Event ID:
145783
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145783
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/22/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Sunrise Skilled Nur & Rehab
333 South Wrightsman Street
Virden, IL 62690
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0757
Level of Harm - Immediate
jeopardy to resident health or
safety
11.6-14.5); INR level of greater than 10 (normal range is 0.9-1.1 with a suggested therapeutic range of 2-3);
FOB (Fecal Occult Blood) was positive. R2 received four blood transfusions on 5/9/25 and one on 5/13/25.
R2's Final pathological diagnosis from the colon biopsies, dated 5/15/25, documents a colon/cecal mass
that is an invasive moderately differentiated adenocarcinoma, the colon showed fragments of tubulovillous
adenoma.
Residents Affected - Few
R2's Colorectal Surgery Consult, dated 5/15/25, documents R2 has a history of DVT(Deep Vein
Thrombosis)/PE on Warfarin, Hgb 3.8, Supratherapeutic INR greater than 10, reversal with Kcentra.
admitted to ICU. EGD (Esophagogogastroduodenoscopy) and colonoscopy revealed a large cecal mass as
well as a foreign body within the cecum, likely a bone.
R2's Cardiology Consult, dated 5/17/25, documents R2 has a history of subsegmental PE (Pulmonary
Embolism), admitted for acute blood loss anemia with a Supratherapeutic INR greater than 10. Continue
holding Coumadin (Warfarin).
R2's Face Sheet, Undated, documents R2 has a diagnosis of Pulmonary Embolism and Atherosclerosis of
the Arteries of the Bilateral Lower Extremities.
R2's Physician Order Sheet (POS), has the following orders: 3/6/25 Warfarin 6 mg (milligrams) every
evening for Pulmonary Embolism and 4/23/25 Check a PT/INR (Prothrombin Time/Initial Normalized Ratio)
weekly on Mondays.
R2's Care Plan, dated, 9/23/22, documents R2 is at high Risk For Abnormal Bruising or Bleeding Related
to Anticoagulant Therapy with Warfarin and an intervention to conduct therapeutic lab monitoring and report
results as ordered by physician or anticoagulant clinic.
R2's last PT/INR was completed on 3/26/25. There were no other PT/INR results completed after this date.
A fax to V6, R2's Physician, dated 4/23/25, from V2, DON (Director of Nurses), documents that R2 had not
had a PT/INR since 3/26/25 and V6 ordered a PT/INR to be completed weekly.
On 5/20/25 at 11:50 AM, V6, R2's Physician, stated verified that he gave an order on 4/23/25 to check R2's
PT/INR weekly. V6 stated R2 is on Warfarin and a residents therapeutic INR level is dependent on what
they are on it for. V6 stated he would need to re-evaluate R2's Warfarin. V6 stated an INR of 10 is not ideal
because it allows bleeding and could lead to a person bleeding to death.
V7, RDO (Regional Director of Operations), stated V2, DON, identified a problem with the PT/INR's not
being drawn so they did a past non-compliance, have in-serviced and are completing audits.
On 5/20/25 at 12:49 PM, V2, DON, stated R2's PT/INR's should have been drawn weekly after 4/23/25 as
they were routine. V2 stated R2 should have been drawn on 5/5/25 and wasn't. V2 stated she called the lab
and was told that it wasn't drawn because there was no carbon copy with the lab requisition, but that it still
should have been drawn.
The Anticoagulant Policy/Procedure, dated 11/4/20, documents the following: The facility shall provide
anticoagulation medications and perform surveillance as directed by the primary care physician
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145783
If continuation sheet
Page 2 of 4
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145783
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/22/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Sunrise Skilled Nur & Rehab
333 South Wrightsman Street
Virden, IL 62690
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0757
Level of Harm - Immediate
jeopardy to resident health or
safety
Residents Affected - Few
and/or facility medical director. The Physician should adjust the anticoagulant dose or stop, taper, or change
medications that interact with the anticoagulant, and/or monitor the PT/INR very closely while the individual
is receiving Warfarin, to ensure that the PT/INR stabilizes within a therapeutic range. They physician will
order appropriate lab testing to monitor anticoagulant therapy and potential complications; for example,
periodically checking hemoglobin/hematocrit, platelets, PT/INR, and stool for occult blood. If Warfarin is
used the staff should use a Warfarin flow sheet or come comparable means to follow trends in
anticoagulant dosage and response in individuals on Warfarin.
The Immediate Jeopardy that began on 4/23/25 was removed on 5/22/25, when the facility took the
following actions to remove the immediacy:
1)
Immediate actions taken for residents identified:
R2 was hospitalized for Supratherapeutic INR on May 7th, 2025, and received medication to reverse the
effects from the anticoagulant, Warfarin.
An audit of all resident laboratory orders was completed on May 9th, 2025, by V2, Director of Nursing.
An audit of all residents that have physician orders for Warfarin were identified and have active lab orders
for PT/INRs to monitor for therapeutic effectiveness was completed by V2, Director of
Nursing, on May 9th, 2025.
2)
How the facility identified other residents who could potentially be affected:
All residents have the potential to be affected by the alleged deficient practice.
3)
Measures put into place/ System changes:
Facility licensed nursing staff were educated by phone or in person in the following categories:
Obtaining laboratory testing as ordered by the physician, with special consideration for those residents on
Warfarin on May 9th, 2025, by V2, Director of Nursing.
Audit of all scheduled labs was completed on May 9th, 2025, including PT/INRs by V2, Director of Nursing.
Audit of all residents with Warfarin medication orders were ensured to have scheduled laboratory testing of
PT/INRs to monitor for therapeutic effectiveness by V2, Director of Nursing on May 9th,
2025.
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145783
If continuation sheet
Page 3 of 4
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145783
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/22/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Sunrise Skilled Nur & Rehab
333 South Wrightsman Street
Virden, IL 62690
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0757
Level of Harm - Immediate
jeopardy to resident health or
safety
Residents Affected - Few
V2, Director of Nursing, initiated a Warfarin tracking system that consists of reviewing the Electronic
Medical Record to ensure that any resident with new orders for Warfarin have orders in place for
monitoring therapeutic effectiveness with a PT/INR laboratory testing and results are obtained and the
resident's physician are notified of those results with new orders obtained as necessary.
Licensed agency staff will not work at the facility until they are educated by the Director of
Nursing/Designee on the importance of ensuring PT/INR levels are ordered with Warfarin to monitor for
therapeutic effectiveness.
The facility will educate all Agency and Facility licensed nursing staff on a quarterly basis and during
orientation on the order process for labs, with emphasis on the need for therapeutic monitoring for
effectiveness for residents with medication orders for Warfarin, by the Director of Nursing or Designee.
4) Those that reviewed policies were:
V19, Chief Nursing Officer, V7, Regional Director of Operations, and V8, Chief Operating Officer
5) How the corrective actions will be monitored:
The Director of Nursing or designee has put into place a Warfarin tracking system that consists of reviewing
the Electronic Medical Record to ensure that any resident with new orders for Warfarin
have orders in place for monitoring therapeutic effectiveness with a PT/INR laboratory testing and results
are obtained and the resident's physician are notified of those results with new orders
obtained as necessary.
The Director of Nursing or designee will complete random audits of scheduled laboratory testing as ordered
by the physician, with special consideration for those residents on warfarin for 12 weeks
until compliance is achieved.
Results of the above reviews will be discussed at a weekly quality assurance meeting that the Administrator
is the head of/holds for a period of 12 weeks and will provide additional education as
needed and implement interventions for improvement until resolution.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145783
If continuation sheet
Page 4 of 4